Plasticell Completes $5.6M Financing Round | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Plasticell today said that it has completed a £3.5 million ($5.6 million) two-part equity financing.

The London-based maker of high-throughput technologies for directed stem cell differentiation, said that it will use the funds to expand its business development and marketing activities as it attempts to grow its customer base. The company has developed the CombiCult technology, which is used to develop stem cell differentiation protocols.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.